



## ANTIMICROBIAL SUSCEPTIBILITIES

### PARTICIPANT STATISTICS

### SECOND QUADRIMESTER 2018

#### ANTIMICROBIAL SUSCEPTIBILITIES vs. *Escherichia coli*

Antimicrobial Agent	*CLSI Group	Code	Resistant				Intermediate				Susceptible					
			A-D	Bkpt	MIC	Total	Code	A-D	Bkpt	MIC	Total	Code	A-D	Bkpt	MIC	Total
Amikacin	B	102	0	0	0	0	202	0	0	0	0	302	14	4	20	38
Amoxicillin/clavulanate	B	104	0	0	0	0	204	2	0	0	2	304	27	10	20	57
Ampicillin	A	105	54	11	33	98	205	0	0	0	0	305	0	0	0	0
Ampicillin/sulbactam	B	107	0	0	4	4	207	1	6	21	28	307	2	0	0	2
Aztreonam	C	110	0	0	0	0	210	0	0	0	0	310	1	5	14	20
Cefazolin	A	116	0	0	0	0	216	1	0	0	1	316	14	11	33	58
Cefepime	B	109	0	0	0	0	209	0	0	0	0	309	2	7	31	40
Cefotaxime	B	125	0	0	0	0	225	0	0	0	0	325	5	5	10	20
Cefoxitin	B	128	0	0	0	0	228	0	0	0	0	328	4	6	11	21
Ceftazidime	C	129	0	0	0	0	229	0	0	0	0	329	12	6	31	49
Ceftriaxone	B	132	0	0	0	0	232	0	0	0	0	332	26	6	31	63
Cefuroxime/Cef Axetil	B	134	0	0	0	0	234	1	0	0	1	334	8	4	9	21
Cephalothin	U	137	3	0	0	3	237	5	2	0	7	337	16	0	2	18
Ciprofloxacin	B	141	0	0	0	0	241	0	0	0	0	341	55	9	37	101
Ertapenem	B	112	0	0	0	0	212	0	0	0	0	312	2	5	29	36
Gentamicin	A	153	1	0	0	1	253	0	0	0	0	353	38	12	36	86
Imipenem	B	155	0	0	0	0	255	0	0	0	0	355	7	8	27	42
Levofloxacin	B	154	0	0	0	0	254	0	0	0	0	354	23	9	35	67
Meropenem	B	163	0	0	0	0	263	0	0	0	0	363	0	2	14	16
Nitrofurantoin	U	171	0	0	0	0	271	0	0	0	0	371	52	10	31	93
Norfloxacin	U	173	0	0	0	0	273	0	0	0	0	373	10	0	0	10
Piperacillin/Tazobactam	B	181	0	0	0	0	281	0	0	0	0	381	3	7	30	40
Tetracycline	C	189	0	0	0	0	289	0	0	0	0	389	40	5	13	58
Tobramycin	A	194	0	0	0	0	294	0	0	0	0	394	4	9	23	36
Trimethoprim/sulfameth	B	197	0	0	0	0	297	0	0	0	0	397	55	12	35	102

**Correct responses for Antimicrobial Susceptibilities are defined as those reflecting agreement among 90% or more of all participants. Unacceptable responses are demonstrated by shading.**

\* CLSI suggested grouping of U. S. FDA-Approved Antimicrobial Agents that should be considered for routine testing and reporting on this organism

- |  |  |
|--|--|
| Group A - Primary Test & Report                                      | Group C - Supplemental, Report Selectively |
| Group B - Primary Test, Report Selectively                           | Group U - Supplemental, For Urine Only     |
| Group O - Other, Not Routine, Clinical Indication for Organism Group |  |

Per CMS requirements, participants will be flagged for inappropriate selection of Antimicrobial Agents as listed in CLSI (NCCLS) guidelines M2- and M7-A6. Scoring will be affected by selection of an incorrect Antimicrobial and will be counted as incorrect whether or not the organism's antimicrobial susceptibility was determined correctly. Antimicrobial agents that are not listed in the CLSI guidelines as appropriate for the identified organism that were reported are:

- Cephalexin
- Tigecycline